androgen ablation

(redirected from androgen suppression)
Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.
Related to androgen suppression: Androgen Deprivation Therapy, androgen ablation

androgen ablation

The therapeutic reduction of circulating androgens (testosterone and 5alpha-dihydrotestosterone) by either orchiectomy or by an luteinizing hormone-releasing hormone (LHRH) agonist. Androgen ablation is commonly used in metastatic prostate cancer and results in disease attenuation (12–18 months) in up to 80% of patients. Androgen ablation can be augmented by flutamide, an androgen receptor antagonist that blocks the effect of androgens produced by the adrenal gland.
References in periodicals archive ?
Medical versus surgical androgen suppression therapy for prostate cancer: A 10-year longitudinal cost study.
He has been using intermittent androgen suppression for more than 5 years in his patients and said the difference in quality of life is striking for these men.
When you think of cancer therapy, you tend to think of weight loss, but men who undergo combined androgen suppression therapy often gain 1520 pounds.
According to the report, higher dose radiation (over 76-78 Gy) combined with androgen suppression therapy is commonly used to treat prostate cancer.
The Phase III Protocol of Androgen Suppression (AS) and 3DCTR/ IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer (RTOG 0521) trial (4) randomized 562 men with high-risk localized prostate cancer treated with radiation and two years of androgen deprivation therapy (ADT), with and without the addition of adjuvant docetaxel (six cycles) and prednisone starting four weeks after radiation.
New guidelines for the use of androgen suppression and possible benefits from combinations with radiation therapy are described in this report.
The Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) study included 122 patients with intermediate- and high-risk PCa.
Celestia Higano at the University of Washington is conducting a Phase II study of exisulind in patients with prostate cancer who are being treated with intermittent androgen suppression.
While there is agreement about the need for androgen suppression in hormone-sensitive prostate cancer, optimal testoster-one levels on ADT remains a matter of debate.
21] on exercise and cancer determined that exercise is a safe and effective means of reducing many of the side effects associated with prostate cancer treatment and androgen suppression.

Full browser ?